Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Abstract Background The RANK pathway has been extensively investigated for its role in bone resorption; however, its significance extends beyond bone metabolism. Preclinical models suggest that inhibition of RANK signaling can prevent mammary tumor development by reducing proliferation and tumor cel...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Anna Petit, M. Teresa Soler-Monsó, Marina Ciscar, Alexandra Barranco, Gema Pérez-Chacón, María Jimenez, Mario Rodríguez, Clara Gomez-Aleza, Elvira Purqueras, Enrique Hernández-Jiménez, Ander Urruticoechea, Idoia Morilla, Isaac Subirana, Amparo García-Tejedor, Miguel Gil-Gil, Sonia Pernas, Catalina Falo, Eva Gonzalez-Suarez
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Breast Cancer Research
Subjects:
Breast cancer
RANK
RANKL
Denosumab
TILs
Immune enhancer
Online Access:https://doi.org/10.1186/s13058-025-01996-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-01996-w

Similar Items